barclays illumina - Search News

Illumina, China and Ban

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego-based Illumina is lowering its 2025 guidance to $4.

Markets Insider · 2d

Illumina guidance cut largely as expected, says Barclays

Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked,

Seeking Alpha · 3d

Illumina lowers guidance, cuts spending to mitigate China ban on its gene sequencers

Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its gene sequencers. Read more here.

Barclays Remains a Sell on Illumina (ILMN)

In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina (ILMN – Research Report), with a price target of ...

Nasdaq2d

Illumina Unusual Options Activity

An analyst from Barclays downgraded its action to Underweight with a price target of $100. * An analyst from Canaccord Genuity persists with their Hold rating on Illumina, maintaining a target ...

San Diego Union-Tribune10d

Illumina cuts workforce at San Diego headquarters

Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Illumina, China and Ban

Trending now